• Corpus ID: 199381326

Ecopipam as a pharmacologic treatment of stuttering.

  title={Ecopipam as a pharmacologic treatment of stuttering.},
  author={Gerald A. Maguire and Lisa R. LaSalle and Debra Hoffmeyer and Michele A. Nelson and Jeannie D. Lochhead and Kendrick A. Davis and Alicia Burris and J. Scott Yaruss},
  journal={Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists},
  volume={31 3},
  • G. Maguire, L. LaSalle, J. Yaruss
  • Published 1 August 2019
  • Linguistics
  • Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
BACKGROUND Stuttering, also known as childhood-onset fluency disorder, is a chronic neurodevelopmental disorder that affects 1% of the population and can greatly impact an individual's social, occupational, and academic functioning. Prior research has shown dopamine D2 antagonists are effective in reducing the severity of stuttering symptoms, but these compounds can be associated with metabolic and movement disorder adverse effects. Ecopipam is an investigational medication that acts as a… 
6 Citations

Tables from this paper

The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis
This review seeks to highlight the different treatment options to help guide the practicing clinician in the treatment of stuttering.
Speech Fluency Improvement in Developmental Stuttering Using Non-invasive Brain Stimulation: Insights From Available Evidence
A review of recent advancements being applied to the treatment of developmental stuttering focuses future research toward more specific, targeted, and effective interventions for DS, based on neuromodulation of brain functioning.
Speech Fluency Disorders: A Review of Studies Conducted Over the Past Five Decades (1970-2020)
Extensive data concerning different perspectives of SFD is published globally, and projected better understanding of most speech disfluencies, Nonetheless, research need to be conducted to develop and provide better quality services to all PWS and to reduce the discrimination against PWS around the world.
New Medications for Neuropsychiatric Disorders.
Positron Emission Tomography studies of the D 1 dopamine receptor in schizophrenia THESIS FOR DOCTORAL DEGREE ( Ph . D . ) By Per Stenkrona
The result of the study does not support the prediction that selective D1R antagonism have antipsychotic effect in schizophrenia and the results suggest that the choice of ROI delineation method is not an important condition for reliability, whereas thorough movement correction is of importance.


A case series on the effectiveness of lurasidone in patients with stuttering.
  • Janet Charoensook, G. Maguire
  • Linguistics
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2017
This open-label study of lurasidone in patients with stuttering showed improvement in subjective symptoms, in CGI scores, and on the SSS scale.
Alleviating stuttering with pharmacological interventions
Novel dopamine antagonists such as risperidone and olanzapine, have recently been shown to improve the symptoms of stuttering providing a strong foundation for physicians to more effectively treat this disorder.
A review of brain circuitries involved in stuttering
A critical review of the literature on stuttering, with particular reference to the role of the basal ganglia, provides evidence of a dysfunctional hyperdopaminergic state of the thalamocortical pathways underlying speech motor control in stuttering.
The pharmacology of stuttering: a critical review.
  • J. Brady
  • Linguistics
    The American journal of psychiatry
  • 1991
Promising avenues of research, both for the treatment of stuttering and for exploring its nature, include the use of calcium channel blocking agents and cholinergic drugs.
Exploratory Randomized Clinical Study of Pagoclone in Persistent Developmental Stuttering: The EXamining Pagoclone for peRsistent dEvelopmental Stuttering Study
Pagoclone was effective in reducing symptoms of stuttering and was well tolerated, and may have potential as a pharmacological treatment of stuttered.
Relapse following treatment for stuttering: a critical review and correlative data
Risperidone for the treatment of stuttering.
The results of this small study indicate that risperidone may be effective in the treatment of developmental stuttering, but this finding needs to be confirmed in a larger trial.